AIMS: Thiazolidinediones increase circulating adiponectin. We have previously demonstrated the involvement of the phosphatidylinositol 3-kinase (PI3K) signaling pathway in insulin-stimulated adiponectin secretion. We therefore investigated the effects of the thiazolidinedione pioglitazone on acute adiponectin secretion, and the involvement of the PI3K signaling pathway in this action. MAIN METHODS: We treated murine 3T3-L1 and human primary adipocytes with 1-10 uM pioglitazone for 2 h, +/-PI3K inhibition by Wortmannin (WT). Secreted adiponectin was measured by Western blot. PI3K activity following 15-minute treatments with 1-10 uM pioglitazone was measured by thin layer chromatography. Pioglitazone's effect on adiponectin synthesis and on secretion of newly synthesized adiponectin was studied in 3T3-L1 adipocytes using a pulse-chase technique. KEY FINDINGS: Pioglitazone was found to increase adiponectin secretion and PI3K activity in a dose-dependent manner from 3T3-L1 and human adipocytes. In 3T3-L1 adipocytes, 10 uM pioglitazone increased adiponectin secretion by 84+/-14% (p<0.0001) at 2 h. Similarly, in human adipocytes there was a 56+/-18% (p<0.02) increase in secretion. WT blocked the pioglitazone effect and decreased adiponectin secretion at 2 h (47% of pioglitazone treated, p<0.006). Pioglitazone increased PI3K activity in a dose-dependent manner in both 3T3-L1 (1.7 vs. 2.7-fold increase over control at 2 uM vs. 10 uM dose, p=0.02) and human adipocytes. SIGNIFICANCE: Our data show that pioglitazone acutely stimulates adiponectin secretion from both 3T3-L1 and human adipocytes. This acute effect of pioglitazone is PI3K-dependent.
AIMS: Thiazolidinediones increase circulating adiponectin. We have previously demonstrated the involvement of the phosphatidylinositol 3-kinase (PI3K) signaling pathway in insulin-stimulated adiponectin secretion. We therefore investigated the effects of the thiazolidinedionepioglitazone on acute adiponectin secretion, and the involvement of the PI3K signaling pathway in this action. MAIN METHODS: We treated murine 3T3-L1 and human primary adipocytes with 1-10 uM pioglitazone for 2 h, +/-PI3K inhibition by Wortmannin (WT). Secreted adiponectin was measured by Western blot. PI3K activity following 15-minute treatments with 1-10 uM pioglitazone was measured by thin layer chromatography. Pioglitazone's effect on adiponectin synthesis and on secretion of newly synthesized adiponectin was studied in 3T3-L1 adipocytes using a pulse-chase technique. KEY FINDINGS:Pioglitazone was found to increase adiponectin secretion and PI3K activity in a dose-dependent manner from 3T3-L1 and human adipocytes. In 3T3-L1 adipocytes, 10 uM pioglitazone increased adiponectin secretion by 84+/-14% (p<0.0001) at 2 h. Similarly, in human adipocytes there was a 56+/-18% (p<0.02) increase in secretion. WT blocked the pioglitazone effect and decreased adiponectin secretion at 2 h (47% of pioglitazone treated, p<0.006). Pioglitazone increased PI3K activity in a dose-dependent manner in both 3T3-L1 (1.7 vs. 2.7-fold increase over control at 2 uM vs. 10 uM dose, p=0.02) and human adipocytes. SIGNIFICANCE: Our data show that pioglitazone acutely stimulates adiponectin secretion from both 3T3-L1 and human adipocytes. This acute effect of pioglitazone is PI3K-dependent.
Authors: Zhouji Chen; Patrick A Vigueira; Kari T Chambers; Angela M Hall; Mayurranjan S Mitra; Nathan Qi; William G McDonald; Jerry R Colca; Rolf F Kletzien; Brian N Finck Journal: J Biol Chem Date: 2012-05-23 Impact factor: 5.157
Authors: R Krishnapuram; E J Dhurandhar; O Dubuisson; H Kirk-Ballard; S Bajpeyi; N Butte; M S Sothern; E Larsen-Meyer; S Chalew; B Bennett; A K Gupta; F L Greenway; W Johnson; M Brashear; G Reinhart; T Rankinen; C Bouchard; W T Cefalu; J Ye; R Javier; A Zuberi; N V Dhurandhar Journal: Am J Physiol Endocrinol Metab Date: 2011-01-25 Impact factor: 4.310
Authors: Sybille Kenzel; Miriam Mergen; Julius von Süßkind-Schwendi; Julia Wennekamp; Sachin D Deshmukh; Monika Haeffner; Antigoni Triantafyllopoulou; Sebastian Fuchs; Susan Farmand; Sandra Santos-Sierra; Jochen Seufert; Timo K van den Berg; Taco W Kuijpers; Philipp Henneke Journal: J Immunol Date: 2012-09-26 Impact factor: 5.422
Authors: William G Sanders; Huan Li; Ilya Zhuplatov; Yuxia He; Seong-Eun Kim; Alfred K Cheung; Jayant Agarwal; Christi M Terry Journal: J Control Release Date: 2017-09-01 Impact factor: 9.776
Authors: David B Briggs; Christopher M Jones; Ellene H Mashalidis; Martha Nuñez; Andrew C Hausrath; Vicki H Wysocki; Tsu-Shuen Tsao Journal: Biochemistry Date: 2009-12-29 Impact factor: 3.162
Authors: Wenpu Zhao; Seth G Thacker; Jeffrey B Hodgin; Hongyu Zhang; Jeffrey H Wang; James L Park; Ann Randolph; Emily C Somers; Subramaniam Pennathur; Matthias Kretzler; Frank C Brosius; Mariana J Kaplan Journal: J Immunol Date: 2009-07-20 Impact factor: 5.422
Authors: Susan A Phillips; Jacqueline Kung; Theodore P Ciaraldi; Charles Choe; Louis Christiansen; Sunder Mudaliar; Robert R Henry Journal: Am J Physiol Endocrinol Metab Date: 2009-07-21 Impact factor: 4.310
Authors: Cecilia C Low Wang; Li Lu; J Wayne Leitner; Mohammad Sarraf; Roberto Gianani; Boris Draznin; Clifford R Greyson; Jane E B Reusch; Gregory G Schwartz Journal: J Diabetes Complications Date: 2013-04-02 Impact factor: 2.852